Evidence map›Paper›PMID 30837169›Full record

ArticleBioorganic & medicinal chemistry2019

Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1.

Safaa M Kishk, Kirsty J McLean, Sakshi Sood, Mohamed A Helal, Mohamed S Gomaa, Ismail Salama, Samia M Mostafa, Luiz Pedro S de Carvalho, Andrew W Munro, Claire Simons

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. pH-Dependent Luminescence of Self-Assembly TbChemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Activation modes in biocatalytic radical cyclization reactions.Journal of industrial microbiology & biotechnology · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Safaa M KishkSchool of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK; Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Kirsty J McLeanManchester Institute of Biotechnology, School of Chemistry, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
Sakshi SoodMycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Mohamed A HelalMedicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt; Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza 12588, Egypt.
Mohamed S GomaaMedicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt; Department of Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Ismail SalamaMedicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Samia M MostafaMedicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Luiz Pedro S de CarvalhoMycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Andrew W MunroManchester Institute of Biotechnology, School of Chemistry, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
Claire SimonsSchool of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK. Electronic address: simonsc@cardiff.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/I019227/1Biotechnology and Biological Sciences Research Council BB/R009961/1Cancer Research UK FC001060Medical Research CouncilWellcome Trust 104785/B/14/ZWellcome Trust FC001060
6 · The paper itself

Abstract

The rise in multidrug resistant (MDR) cases of tuberculosis (TB) has led to the need for the development of TB drugs with different mechanisms of action. The genome sequence of Mycobacterium tuberculosis (Mtb) revealed twenty different genes coding for cytochrome P450s. CYP121A1 catalyzes a CC crosslinking reaction of dicyclotyrosine (cYY) producing mycocyclosin and current research suggests that either mycocyclosin is essential or the overproduction of cYY is toxic to Mtb. A series of 1,4-dibenzyl-2-imidazol-1-yl-methylpiperazine derivatives were designed and synthesised as cYY mimics. The derivatives substituted in the 4-position of the phenyl rings with halides or alkyl group showed promising antimycobacterial activity (MIC 6.25 μg/mL), with the more lipophilic branched alkyl derivatives displaying optimal binding affinity with CYP121A1 (

Indexed as

Antitubercular AgentsCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDipeptidesDrug DesignHumansMolecular Docking SimulationMycobacterium tuberculosisPeptides, CyclicPiperazinesTuberculosisAntitubercular Agentscyclo(tyrosyl-tyrosyl)cytochrome P-450 CYP12A1 (house fly)Cytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDipeptidesPeptides, CyclicPiperazines1,4-Dibenzyl-2-imidazol-1-yl-methylpiperazine derivativesBinding affinity assaysCYP121A1Molecular modellingMycobacterium tuberculosis

Identifiers

PMID30837169
PMCPMC7049898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.